Krystal Biotech, Inc. KRYS

Latest FY: 2025 Healthcare Biotechnology
Market Price $332.07
Market Cap $9.69B
P/E Ratio 48.55
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑33.9% YoY
$389.13M
Full year reported
Net Income ↑129.7% YoY
$204.83M
Net Margin: 52.6%
Free Cash Flow ↑58.5% YoY
$188.91M
FCF Yield: 1.95%
EPS (Diluted) ↑128.0% YoY
$6.84
Basic: $7.08
Return on Equity Efficiency
16.8%
ROA: 1,374.2%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (KRYS)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2019: Revenue YoY (+300.0%) is identical to Gross Profit YoY (+300.0%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $-1.1M $-1.31 $-1.3M $-1.3M
FY 2017 $-7.9M -588.7% $-1.48 -13.0% $-3.9M $-4.1M -209.2%
FY 2018 $0.0M $0.0M $-10.9M -37.5% $-0.97 +34.5% $-9.4M $-11.7M -184.9%
FY 2019 $0.0M +300.0% $0.0M $-19.1M -75.3% $-1.20 -23.7% $-18.7M $-25.1M -115.0%
FY 2020 $-0.0M -150.0% $-32.2M -68.5% $-1.71 -42.5% $-26.1M $-40.9M -63.0%
FY 2021 +100.0% $-69.6M -116.3% $-3.13 -83.0% $-47.9M $-116.3M -184.1%
FY 2022 $-140.0M -101.2% $-5.49 -75.4% $-100.6M $-153.5M -32.1%
FY 2023 $50.7M $47.6M $10.9M +107.8% $0.39 +107.1% $-88.8M $-100.6M +34.5%
FY 2024 $290.5M +473.0% $270.5M $89.2M +715.6% $3.00 +669.2% $123.4M $119.2M +218.5%
FY 2025 $389.1M +33.9% $366.1M $204.8M +129.7% $6.84 +128.0% $200.9M $188.9M +58.5%
$

Valuation

Market Price $332.07
Market Cap $9.69B
Enterprise Value N/A
P/E Ratio 48.55
P/B Ratio 8.03
FCF Yield 1.95%
Dividend Yield N/A
Shares Outstanding 29,479,800
%

Profitability & Margins

Gross Margin 94.08%
Operating Margin 41.45%
Net Margin 52.64%
Return on Equity (ROE) 16.80%
Return on Assets (ROA) 1,374.24%
Asset Turnover 26.11x
Revenue 3-Yr CAGR N/A
🛡️

Financial Health & Liquidity

Current Ratio 0.14
Cash Ratio 4.82
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $496.30M
Total Debt N/A
Book Value / Share $41.37
💧

Cash Flow Efficiency

Operating Cash Flow $200.87M
Capital Expenditures (CapEx) $11.95M
Free Cash Flow $188.91M
OCF / Revenue 51.62%
FCF / Revenue 48.55%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $6.84
EPS (Basic) $7.08
Dividends / Share N/A
Book Value / Share $41.37
EPS YoY Growth 128.00%
🏛️

Balance Sheet (FY 2025)

Total Assets $14.90M
Total Liabilities $102.94M
Stockholders' Equity $1.22B
Current Assets $14.90M
Current Liabilities $102.94M